Iatrogenic botulism

Iatrogenic botulism is a rare form of botulism that occurs as an unintended consequence of medical or cosmetic procedures involving botulinum toxin injections. Unlike naturally occurring forms of botulism (foodborne, wound, or infant botulism), iatrogenic botulism results from the therapeutic or cosmetic use of botulinum neurotoxin (such as onabotulinumtoxinA, abobotulinumtoxinA, or other formulations) when the toxin spreads beyond the intended injection site or is administered in excessive doses. Botulinum toxin blocks the release of acetylcholine at the neuromuscular junction, and when this effect extends systemically, it can cause generalized muscle weakness and potentially life-threatening complications. The condition primarily affects the neuromuscular system. Key clinical features include progressive descending flaccid paralysis, dysphagia (difficulty swallowing), dysarthria (difficulty speaking), diplopia (double vision), ptosis (drooping eyelids), generalized muscle weakness, and in severe cases, respiratory failure requiring mechanical ventilation. Symptoms typically develop within days to weeks following the injection procedure. Autonomic dysfunction, including dry mouth, constipation, and urinary retention, may also occur. Treatment is primarily supportive and may include intensive care monitoring, mechanical ventilation for respiratory compromise, and nutritional support. Botulinum antitoxin may be considered in severe cases, though its efficacy in iatrogenic botulism is not as well established as in foodborne botulism, particularly because the toxin may already be bound at nerve terminals by the time symptoms develop. Recovery is generally gradual, occurring over weeks to months as new nerve terminals regenerate. Prevention focuses on careful dosing, proper injection technique, and awareness of patient-specific risk factors that may predispose to toxin spread.

Common questions about Iatrogenic botulism